How do biotechs build a defensible data moat?
Costs keep doubling while approvals don't, how do I turn continuous monitoring into portfolio decisions and a moat that actually compounds?
~90% of drugs fail, and the costly mistake is stopping too late - €10M at lab stage versus €1B at human. In a custom build on the PharosBio Clinical Trial Retriever API, we connected early-stop monitoring to portfolio strategy: where to cut and where to redirect budget, the preclinical entry wedge, and the commercial case in a market growing from ~$31.7B to ~$64B by 2030.
Who this is for: Executives, business-development, and strategy leaders shaping portfolio direction and building a defensible data moat.
- of drugs fail - usually by stopping too late
- ~90%
- cost of failing at lab vs human stage
- €10M → €1B
- AI drug-discovery market by 2030 (~15% CAGR)
- $31.7B → $64B
- API also available as a skill in Hydra
- custom build
of drugs fail - usually by stopping too late
cost of failing at lab vs human stage
AI drug-discovery market by 2030 (~15% CAGR)
API also available as a skill in Hydra
Why monitoring alone doesn't move the needle
The backdrop is Eroom's law: large-pharma R&D spend has roughly doubled over ten years, yet the industry still delivers around fifty drugs a year at a success rate below ten percent. Costs keep doubling; approvals don't. Against that headwind, simply tracking the landscape isn't enough.
The strategic questions are what to do with the monitoring: where is the unaddressed need, which direction is defensible, and how does today's data make tomorrow's position stronger rather than just better-informed? For a company raising capital, that defensibility is the entire story, investors price a compounding asset very differently from one that merely runs studies.
What teams in this space search for
- How do biotechs build a defensible data moat?
- How do I find white space in oncology?
- Why does drug R&D keep getting more expensive (Eroom's law)?
How we built it
A custom strategy build on the PharosBio Clinical Trial Retriever API - the same engine behind the monitoring work. It links early-stop signals (publications, safety, clinical outcomes, PK/PD, IC50) to budget decisions, and frames the commercial case: where to redirect spend, the preclinical entry wedge, and AI-pharma deal economics.
How the pipeline works
Strategy starts where monitoring leaves off. The same live board that flags a failing asset also says where to redirect: cut losses on the asset whose probability is sliding, and move that budget to the one with momentum. On the example board the recommendation is explicit - redirect ~€2M from a stalling diabetes asset to accelerate an oncology asset with strong week-12 data.
We tie that to the commercial picture. The entry wedge is preclinical - ~1.9 million animal studies a year, largely untouched by incumbents - monetised first as SaaS, then per asset. The market is moving from ~$31.7B to ~$64B by 2030 (≈15% CAGR), and AI-pharma licensing deals average ~$37M upfront and ~$1.6B total, about $8.5M per asset.
What it found
The strategic payoff is fail-fast, scale-faster: cutting a losing programme before Phase 1 can save tens of millions, while the freed budget accelerates the assets most likely to succeed. The earlier the stop, the larger the saving - the cost curve runs €10M (lab) → €440M (animal) → €1,000M (human).
Because every decision is evidenced and every result captured, the proprietary picture compounds: each analysis starts smarter than the last - the part a competitor without your data and history cannot easily copy.
What we learned
Monitoring alone is informative; strategy is what you do with it. Connecting early-stop signals to budget decisions, and to a clear commercial wedge, is what turns intelligence into ROI.
Like the monitoring work, this was a custom build on the PharosBio Clinical Trial Retriever API, available as a skill in Hydra. The same engine that scores trials can pressure-test where a portfolio is exposed and where the white space is.
A monitored portfolio, refreshed as new evidence lands. Each asset carries a moving success probability; click an alerted asset to see exactly what changed and what to do about it.
| Asset | Indication | Phase | Success prob. | Status |
|---|---|---|---|---|
| Drug A | T2 Diabetes | Preclinical | 32% → 18% | ALERT |
| Drug B | NASH | Preclinical | 71% → 73% | Stable |
| Drug C | Alzheimer's | Preclinical | 45% → 38% | Review |
| Drug D | Oncology | Preclinical | 82% → 85% | PRIORITIZE |
| Drug E | Parkinson's | On Hold | 12% | Stopped |
Drug A - Immediate review recommended
Probability dropped 14 points in 48 hours
What changed
- Competitor failure: A similar GLP-1/GIP dual agonist failed Phase 2 (liver-enzyme elevation in 23% of patients).
- New publication: A JAMA study links GPR40 agonism to hepatotoxicity in patients with pre-existing NAFLD.
- Your data: Week-8 preclinical results show 15% ALT elevation (borderline).
Recommended actions
- Run an extended 12-week tox study with liver monitoring (~€50K, 3 months)
- Test in a NAFLD disease model (~€30K, 6 weeks)
- If signals persist: stop before Phase 1 (save ~€45M)
Click Drug A or Drug D to see why the probability moved.
The cost of stopping too late
~90% of drugs fail. The issue is rarely failure itself - it is stopping too late, after the most expensive studies are already paid for.
competitor Phase 2 readouts
class hepatotoxicity, AE overlap
HR, ORR, PFS by subtype
exposure, potency, model relevance
Agent links them
Call the stop - or the acceleration - earlier
Connect a programme’s own PK/PD and IC50 to the literature and clinical record, and a redirect that would have surfaced after animal studies can surface before them.
The same monitoring that cuts losses early is also the commercial wedge: enter at preclinical, where incumbents are thin, then monetise per asset.
$31.7B → $64B
AI drug-discovery market, 2025 → 2030 (≈15% CAGR)
$37M / $1.6B
average AI-pharma deal: upfront / total value (~$8.5M per asset)
1.9M / yr
animal studies - the preclinical wedge incumbents largely skip
One API, many workflows
This was a custom build for a partner, powered by the PharosBio Clinical Trial Retriever API - which fetches clinical endpoints and scores drug similarity by target and mechanism of action. The same API can be repointed at:
- Safety scoring for combinations
- Extrapolating clinical outcome from in vivo data
- Portfolio monitoring
- Drug repurposing
It is also available as a skill inside Hydra
Run this analysis on your question
Hydra plans, executes, and validates, so you reach a defensible answer in hours, not weeks.
What you get
- A fail-fast / scale-faster rule: cut losing assets early, redirect budget to winners
- Early-stop savings quantified against the €10M → €1B cost curve
- A commercial case: preclinical wedge, market growth, and per-asset deal economics
- A compounding, evidenced picture that a competitor can't easily replicate
Sources & methods
- 01Eroom's law: Scannell et al., Nat Rev Drug Discov 2012
- 02Software 2.0 framing: Karpathy, 2017
Figures reflect analyses PharosBio ran on public datasets and public benchmarks; the methods and results shown are real and repointable to your own target.
Frequently asked questions
What is Eroom's law and why does it matter to strategy?
Eroom's law is the decades-long fall in drug-discovery productivity despite rising investment: R&D spend has roughly doubled in ten years while output holds near ~50 drugs a year at under 10% success. It's the headwind any portfolio strategy has to beat.
What does 'data moat' actually mean here?
Your proprietary data, run through a self-improving loop, produces an advantage that widens with use - each experiment sharpens the next decision. Because the value is the compounding loop rather than one model, a competitor without your data and history can't easily catch up.
Was this built with Hydra?
No - like the monitoring work, it was a custom project for a partner on the PharosBio Clinical Trial Retriever API. That API is also available as a skill in Hydra, so the same early-stop and white-space analysis can be reproduced there.